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Where Are All the Women With Heart Failure?
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Denver, Colorado; Menlo Park, California; and Washington, D.C.
In recent clinical trials of medical therapy for heart failure,
only ;20% of patients enrolled were women. The reasons for
the low enrollment of women have not been clear. Although the
incidence of heart failure is higher in men than in women, the
prevalence is equal. When men and women with heart failure and
a low left ventricular ejection fraction are compared, the women
are more symptomatic and have a similarly poor outcome. Be-
cause mortality is worse in men than in women in large popula-
tions of patients with heart failure, there may be important
pathophysiologic differences. Substantial data suggest that
women may have diastolic dysfunction more often than men. This
difference would explain differences in mortality and the difficulty
in enrolling women in studies of medical therapy for heart failure
with underlying systolic dysfunction.
(J Am Coll Cardiol 1997;30:1417–9)
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Investigators who have been involved in the conduct of clinical
trials of heart failure know that it is difficult to enroll women
with symptomatic heart failure due to systolic dysfunction. In
recent clinical trials (1–10) of medical therapy for heart failure,
only ;20% of the subjects were women (Table 1). This low
enrollment of women has been a puzzling problem. Although
the incidence of heart failure is higher in men than in women
in every age group, the prevalence of heart failure is about the
same in all age groups (Fig. 1) (11). Similar prevalence data
were reported in the National Health and Nutrition Examina-
tion Survey (NHANES-I) (12). The National Institutes of
Health has recommended that there be appropriate represen-
tation of subjects with respect to gender and racial or ethnic
subgroups in clinical trials to provide the opportunity to detect
major qualitative differences among these subgroups (13).
Thus, finding and enrolling women with heart failure and
systolic dysfunction is a problem that is being tackled by every
steering committee directing a clinical trial of medical therapy
for heart failure. These groups find themselves asking, “Where
are all the women with heart failure?” Although the final
answer to this question will await a formal evaluation, sugges-
tive data are already available.
The Studies of Left Ventricular Dysfunction (SOLVD)
registry (14) was implemented in several of the same centers
participating in the SOLVD treatment and prevention trials.
The registry was designed to include a broader spectrum of
patients than those entered into the treatment and prevention
trials. Patients entered into the registry were discovered by
screening reports of cardiac catheterizations, nuclear gated
blood pool scans, and echocardiograms as well as screening
hospital discharge summaries. With this systematic approach,
more women were entered into the registry than into either the
SOLVD treatment or prevention trials. However, only 26% of
the total registry population were women, and they had a
substantially higher average left ventricular ejection fraction
than patients entered into the treatment and prevention trials.
Thus, even an intensive search may not provide equal numbers
of men and women for clinical trials of heart failure with
systolic dysfunction. These data suggest that although there are
large numbers of both men and women with symptomatic heart
failure, important pathophysiologic differences may exist.
Among patients with heart failure, women are more symp-
tomatic than men despite an equivalent left ventricular ejec-
tion fraction (15). Surprisingly, symptoms of heart failure are
more common in women than in men, even when rest systolic
function is normal. In the Coronary Artery Surgery Study
(CASS) (16), women had significantly more heart failure
symptoms and used more diuretic drugs despite a better
ejection fraction and less three-vessel coronary artery disease.
Why does this difference in symptoms exist? Do women have
more diastolic dysfunction than men?
In many clinical trials of heart failure with systolic dysfunc-
tion, the number of patients with hypertension as the primary
etiology for heart failure is low, but the percent of patients with
reported hypertension is high, often more than one-third (2,3).
This incidence of hypertension in patients with heart failure is
consistent with the incidence of hypertension in the United
States, which is estimated to be .50% for patients .60 years
old (17). Thus, hypertension may be underrecognized as an
underlying cause of heart failure. Several studies suggest that
women may have a qualitatively different left ventricular
hypertrophic response to a pressure load than men. In reports
of hypertensive cardiomyopathy of the elderly, .80% of
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patients are women (18). Carroll et al. (19) reported that
women with severe aortic stenosis have more concentric
hypertrophy and better preserved left ventricular systolic func-
tion than men with a similar degree of aortic stenosis. More
eccentric hypertrophy and poorer left ventricular systolic func-
tion were found in the men. In women with isolated systolic
hypertension, concentric hypertrophy was most common,
whereas eccentric hypertrophy was more commonly found in
men (20). If, as suggested by these data, women are more likely
to develop concentric hypertrophy in response to a variety of
loading conditions, one might expect symptoms of heart failure
but with preserved systolic function and thus a better prognosis
than men with more abnormal systolic function. Indeed,
hypertension increases the risk of symptoms of heart failure in
both men and women, but the mortality risk is higher in men
(21,22).
Thus, the data are consistent with the hypothesis that there
is substantially more heart failure due to diastolic dysfunction
in women than in men. An excess of diastolic dysfunction in
women would explain the equal prevalence of heart failure in
men and women in the United States while accounting for the
difficulty in actually finding equal numbers of women and men
with heart failure due to systolic dysfunction. A preponderance
of diastolic dysfunction might also help explain the better
prognosis of women with heart failure. The results of ongoing
clinical trials should provide answers to whether there are
important differences in etiology and pathophysiology in
women compared with men with heart failure.
If differences do exist, there may be differences in morbidity
and mortality and in the response to medical therapy.
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